文献速递造血干细胞移植与细胞治疗

体外扩增供者调节性T细胞有效治疗小鼠急性GVHD

Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells.
PubMed 文献 · Leukemia · 2019-11-12

该研究探讨体外扩增的表型和功能稳定的供者调节性T细胞(Treg)对已建立的小鼠单倍体相合急性移植物抗宿主病(aGvHD)的治疗效果。结果显示,回输供者Treg可改善aGvHD的临床和组织学表现并显著提高生存率。Treg迁移至淋巴组织和aGvHD靶器官(尤其是胃肠道),抑制常规T细胞增殖、减少髓系细胞浸润和炎症因子积聚,且长期存活不转化为致病性效应T细胞。

要点

  • 体外扩增的供者Treg可治疗已建立的小鼠aGvHD,改善症状并提高生存。
  • Treg主要迁移至胃肠道等靶器官,抑制常规T细胞增殖和炎症。
  • 治疗成功的动物可修复组织损伤并支持淋巴细胞重建。

核心结论

  • 供者Treg不仅可预防aGvHD,还能有效治疗这一致命性BMT并发症。

研究设计与样本

  • 使用体外扩增的表型和功能稳定的小鼠Treg,在单倍体相合aGvHD模型中评估治疗 efficacy。

主要发现

  • 回输供者Treg改善aGvHD的临床和组织学体征,并显著提高生存率。
  • Treg迁移至淋巴组织和aGvHD靶器官,以胃肠道为主,抑制常规T细胞增殖、减少髓系细胞流入和炎症因子积聚。
  • 治疗成功的动物修复靶器官和淋巴组织的aGvHD损伤,支持淋巴细胞重建。
  • 治疗用Treg群体长期存活,未转化为致病性效应T细胞。

临床怎么用

  • 提示供者Treg可能用于治疗已建立的aGvHD,但尚需临床研究验证。

局限性

  • 研究仅在小鼠模型中进行,结论外推至人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGvHD) is a frequent complication after allogeneic bone marrow/stem cell transplantation (BMT/SCT) induced by co-transplanted alloreactive conventional donor T cells. We previously demonstrated that the adoptive transfer of donor CD4+CD25+Foxp3+ regulatory T cells (Treg) at the time of BMT prevents aGvHD in murine models. Yet, the therapeutic potential of donor Treg for the treatment of established aGvHD has not yet been studied in detail. We now used in vitro expanded phenotypically and functionally stable murine Treg to explore their therapeutic efficacy in haploidentical aGvHD models. Upon transfer donor Treg ameliorate clinical and histologic signs of aGvHD and significantly improve survival. They migrate to lymphoid as well as aGvHD target organs, predominantly the gastrointestinal tract, where they inhibit the proliferation of conventional T cells, reduce the influx of myeloid cells, and the accumulation of inflammatory cytokines. Successfully treated animals restore aGvHD-induced tissue damage in target organs and lymphoid tissues, thereby supporting lymphocyte reconstitution. The therapeutically applied Treg population survives long term without conversion into pathogenic effector T cells. These results demonstrate that donor Treg not only prevent aGvHD, but are also efficacious for the treatment of this life-threatening BMT complication.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Riegel C, Boeld TJ, Doser K, et al. Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. Leukemia. 2019. PMID: 31719679. doi:10.1038/s41375-019-0625-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。